Trial Profile
A Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MK3102 in Obese Subjects and in Patients With Type 2 Diabetes.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 11 May 2022
Price :
$35
*
At a glance
- Drugs Omarigliptin (Primary)
- Indications Obesity; Type 2 diabetes mellitus
- Focus Adverse reactions
- Sponsors Merck & Co; Merck Sharp & Dohme
- 27 Aug 2019 Results assessing population pharmacokinetic and pharmacodynamic model by using data from phase I, II and III studies including this study published in the British Journal of Clinical Pharmacology.
- 23 Jun 2013 Results presented at the 73rd Annual Scientific Sessions of the American Diabetes Association.
- 26 May 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.